IDiyas

For the Inventor, By the Inventor

The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Patent No.:

US 11951212 B1

PDFFull Text
Date of Patent:
Apr. 09, 2024

Filed:

Mar. 17, 2021

Pharmaceutical compositions for the treatment of cystic fibrosis transmembrane conductance regulator mediated diseases

Applicant:

Vertex Pharmaceuticals Incorporated, Boston, MA (US);

Inventors:

Brian Dean Phenix, Acton, MA (US);

Laurent Jean-Claude Bagnol, Burlington, MA (US);

Geoffrey Glen Brodeur, Somerville, MA (US);

Sachin Chandran, Somerville, MA (US);

Eleni Dokou, Cambridge, MA (US);

Lori Ann Ferris, Medford, MA (US);

Dragutin Knezic, Watertown, MA (US);

Katie Lynn McCarty, Watertown, MA (US);

Ales Medek, Winchester, MA (US);

Sara A. Waggener, N. Billerica, MA (US);

Assignee:

Vertex Pharmaceuticals Incorporated, Boston, MA (US);

Attorney:

Finnegan, Henderson, Farabow, Garrett & Dunner, LLP

Primary Examiner:

Alma Pipic

Int. Cl.
CPC ...
A61K 31/404 (2006.01); A61K 9/14 (2006.01); A61K 9/16 (2006.01); A61K 9/20 (2006.01); A61K 31/443 (2006.01); A61K 31/47 (2006.01); A61K 31/4709 (2006.01); A61K 31/4725 (2006.01); A61K 45/06 (2006.01); C07D 209/04 (2006.01); C07D 215/00 (2006.01); C07D 215/56 (2006.01); C07D 405/12 (2006.01);
U.S. Cl.
CPC ...
A61K 9/14 (2013.01); A61K 9/146 (2013.01); A61K 9/16 (2013.01); A61K 9/1652 (2013.01); A61K 9/2054 (2013.01); A61K 9/2077 (2013.01); A61K 31/404 (2013.01); A61K 31/443 (2013.01); A61K 31/47 (2013.01); A61K 31/4709 (2013.01); A61K 31/4725 (2013.01); A61K 45/06 (2013.01); C07D 209/04 (2013.01); C07D 215/00 (2013.01); C07D 215/56 (2013.01); C07D 405/12 (2013.01);
Abstract

The present invention features compositions comprising a plurality of therapeutic agents wherein the presence of one therapeutic agent enhances the properties of at least one other therapeutic agent. In one embodiment, the therapeutic agents are cystic fibrosis transmembrane conductance regulators (CFTR) such as a CFTR corrector or CFTR potentiator for the treatment of CFTR mediated diseases such as cystic fibrosis. Methods and kits thereof are also disclosed.

Find Patent Forward Citations

Loading…